文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > Adjuvant Imatinib Treatment after R0 Resection for Patients With High-Risk
侵权投诉

Adjuvant Imatinib Treatment after R0 Resection for Patients With High-Risk

JournalofSurgicalOncology

AdjuvantImatinibTreatmentafterR0ResectionforPatientsWithHigh-Risk

GastrointestinalStromalTumors:AMedianFollow-Upof44Months

WEI-ZHONGJIANG,MD,1GUO-XIANGUAN,MD,1HUI-SHANLU,MD,1YING-HONGYANG,

DE-YONGKANG,MD,2ANDHE-GUANGHUANG,MD,PhD1*

1

MD,

2

DepartmentofGeneralSurgery,Af liatedUnionHospital,FujianMedicalUniversity,Fuzhou,People’sRepublicofChina2

DepartmentofPathology,Af liatedUnionHospital,FujianMedicalUniversity,Fuzhou,People’sRepublicofChina

Background:TheoptimaldurationofImatinibadjuvanttreatmentforpatientswithhigh-riskgastrointestinalstromaltumors(GISTs)isuncertain.

PatientsandMethods:Atotalof90patientswithhigh-riskGISTsaftercurativeresectionwererecruitedintothisnon-randomizedcase–controlstudy,including35havingImatinibadjuvanttherapyand55havingfollow-upalone.Therecurrence-freesurvival(RFS)wascompared.

Results:Afteramedianfollow-upof44.0months,asigni cantlyreducedrecurrenceratewasobservedinthetreatmentgroupthanthecontrolgroup(17.1%vs.78.2%,P¼0.000).One-year,2-year,and3-yearRFSrateswere100%vs.70.9%,88.0%vs.37.8%,and88.0%vs.27.5%,respectively;withasigni cantadvantageforImatinibadjuvanttherapyversusthesurgeryonly(P¼0.000,HR0.122,95%CI0.041–0.363).ContinuationImatinibtreatmentfurtherimprovedRFSbycomparisonwiththeinterruptiontreatment(both2-yearand3-yearRFSwere95.8%vs.63.6%,P¼0.011,HR0.103,95%CI0.012–0.883).Therewerenoseriousadverseeventsintheadjuvanttherapygroup.

Conclusions:ImatinibAdjuvanttherapycouldsigni cantlyprolongtheRFSofpatientswithhigh-riskGISTs.ExtendedImatinibadjuvanttreatmentstrategymayfurtherreducetheriskofrelapsewithalowdrugresistancerateandtoxicitypro le.

J.Surg.Oncol.ß2011Wiley-Liss,Inc.

KEYWORDS:GISTs;Imatinib;adjuvanttherapy;recurrence-freesurvival;adverseevents

INTRODUCTION

Incurrentclinicalpractice,completesurgicalresection(R0)remainsthemaintreatmentapproachforgastrointestinalstromaltumors(GISTs).Unfortunately,over85%ofhigh-riskGISTspatientshavelocaltumorrelapseand/ormetastasesevenafteranR0resec-tion,witha5-yearrecurrence-freesurvivalofonly20–40%reported[1–4].Thesetumorsarealsoratherresistanttoradiotherapyandtoconventionalchemotherapy.Thus,developingatreatmentstrategytoreducetumorrecurrenceandprolongoverallsurvival(OS)isveryimportantforthepatientswithhigh-riskdisease.

RecentstudiessuggestthatGISTsarisefromtheinterstitialcellsofCajal.TheyarecharacterizedbyanoverexpressionoftheKITreceptorprotein(CD117)inapproximately80%ofpatients,andCD117hasbecomeapotentialtargetfortherapy[5–7].Imatinibmesylateisaspeci csmall-moleculetyrosinekinaseinhibitorinitiallydevelopedfortreatingChronicMyeloidLeukemia(CML).Ithasbeenshowntohaveclinicalbene tinover80%ofpatientswithmetastaticGISTs,withlowtoxicitypro lereportedinmulticenterclinicaltrialsintheUSandFinland(STIB2222),Europe(EORTCSoftTissueandSarcomaGroup),andAustralia(AustralianGastroIntestinalTrialsGroup).TheB2222trailshowedthat75%ofpatientswithunresectableormetastaticGISTstreatedwithImatinibhadapartialresponseorstablediseasewithamedianOSofapprox-imately57months[8,9].Thesedatahaveledtoquestionsontheadjuvantuseofthisagentforhigh-riskpatientstopreventrecurrenceofafterR0resection.

In2007,Nilssonetal.[10]reportedanobviousRFSadvantageofImatinibadjuvanttherapyforpatientswithGISTswithahigh

malignantpotential.Multiplecurrentprospectiverandomizedtrials(ACOSOGZ9000,ACOSOGZ9001,EORTC,andSSGXVIII)alsohaveaddressedtheroleofImatinibadjuvanttherapyindifferentgroupsofpatients.However,theoptimaldurationofadjuvanttreat-mentisuncertain.Thisstudywastoevaluatetheef cacyandsafetyofextendingImatinibadjuvanttherapyfor5yearsinhigh-riskGISTspatientsafterR0resection.Resultsatamedianfollow-upof44monthswerereportedhere.

PATIENTSANDMETHODS

Patients

FromApril2002toSeptember2009,weprospectivelygatheredclinicaldataon90consecutivepatientswithCD117positivehigh-riskGISTswhohadanR0resectionattheDepartmentofGeneralSurgery,theAf liatedUnionHospitalofFujianMedicalUniversity.Detailedinformationonpatientdemographics,tumorsites,operationperformed,andhistopathologicstudieswereallavailable.The

JiangWZandGuanGXcontributedequallytothiswork.

*Correspondenceto:He-GuangHuang,MD,PhD,DepartmentofGeneralSurgery,Af liatedUnionHospitalofFujianMedicalUniversity,29XinquanRoad,Fuzhou,350001,FujianProvince,People’sRepublicofChina.Fax:86-591-87113828.E-mail:HHUANG2@yahoo.cnReceived3April2011;Accepted8June2011DOI10.1002/jso.22010

PublishedonlineinWileyOnlineLibrary(wileyonlinelibrary.com).

ß2011Wiley-Liss,Inc.

第1页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email